PAS
UTHR icon

Park Avenue Securities’s United Therapeutics UTHR Stock Holding History

Park Avenue Securities’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$562K Buy
1,038
+204
+24% +$115K ﹤0.01% 1233
2026
Q1 		$494K Buy
+834
New +$415K ﹤0.01% 1112
2025
Q4 		– Sell
-984
Closed -$412K – 1693
2025
Q3 		$412K Sell
984
-1,369
-58% -$460K ﹤0.01% 1285
2025
Q2 		$676K Buy
2,353
+39
+2% +$11.7K 0.01% 934
2025
Q1 		$713K Sell
2,314
-300
-11% -$103K 0.01% 727
2024
Q4 		$922K Buy
2,614
+407
+18% +$150K 0.01% 807
2024
Q3 		$791K Buy
2,207
+170
+8% +$57.4K 0.01% 780
2024
Q2 		$649K Buy
2,037
+475
+30% +$126K 0.01% 843
2024
Q1 		$359K Buy
1,562
+155
+11% +$35K ﹤0.01% 1100
2023
Q4 		$309K Buy
1,407
+66
+5% +$15.2K ﹤0.01% 1116
2023
Q3 		$303K Buy
+1,341
New +$309K ﹤0.01% 1045
2023
Q1 		– Sell
-1,116
Closed -$310K – 1145
2022
Q4 		$310K Buy
+1,116
New +$282K 0.01% 969

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Park Avenue Securities's UTHR Position: Q2 2026 in Review

Park Avenue Securities increased its United Therapeutics (UTHR) stake by 24% in Q2 2026, buying an estimated $115K and bringing the position to 1,038 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

Park Avenue Securities first reported a position in UTHR in Q4 2022 and has held it in 12 quarters since. The position peaked at $922K in Q4 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Park Avenue Securities held 1,038 shares of United Therapeutics worth $562K as of Q2 2026.
  • Park Avenue Securities bought 204 United Therapeutics shares in Q2 2026, an estimated $115K.
  • United Therapeutics made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1233 holding.
  • Park Avenue Securities first reported a position in United Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • Park Avenue Securities's United Therapeutics position peaked at $922K in Q4 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.